Pharma channel feed – Endpoints News

Pharma channel feed

The next Sage? Shkreli partner Ligand puts together another sweet startup package deal for Seelos

9 years ago

Out of limbo, Sarepta is raising $225M and taking bids on a priority voucher as it revs up marketing

9 years ago

Long-suffering Eleven hands the reins over to a new CEO with his own pipeline plans

9 years ago

Genentech dives into mRNA, betting $310M on BioNTech's personalized cancer vaccine tech

9 years ago

Allergan goes on a buying spree for NASH drugs, adding Akarna in M&A double header

9 years ago

Say what? Allergan just agreed to pay a 6X cash premium for Tobira and its troubled PhIII NASH drug

9 years ago

Shire wants out of that $172M Baxalta deal with CTI Bio

9 years ago

Sarepta rockets up after FDA approves its controversial Duchenne drug

9 years ago

Aralez finally gets an FDA OK for its cardio drug Yosprala, starts hiring sales reps

9 years ago

The FDA confirms that Sarepta nemesis Ronald Farkas has left the agency

9 years ago

Takeda will transfer 300 staffers to CRO in ongoing R&D overhaul

9 years ago

$354M exit package in hand, Medivation CEO David Hung completes a master class in biotech auctions

9 years ago

Martin Shkreli, the obscene prankster of biotech, makes his final exit at KaloBios

9 years ago

Mylan CEO Bresch hopes to tame the mob with a 50% discount for the EpiPen

9 years ago

AstraZeneca sells off more assets from its island of misfit drugs in $1.6B Pfizer deal

9 years ago

Clovis soars as its PARP drug rucaparib lines up for FDA review with positive data

9 years ago

Google Ventures’ Krishna Yeshwant is hunting for the next big new idea in biotech

9 years ago

Chinese development group blueprints $1B-plus biotech campus in South San Francisco

9 years ago

Portola slammed by a surprising FDA rejection for its anti-anticoagulant

9 years ago

Bind burial complete, Andrew Hirsch lands the CFO’s job at high-profile Agios

9 years ago

What's Gilead's next deal going to look like? CEO Milligan cites blockbuster filgotinib pact

9 years ago

FDA experts unanimously endorse Amgen’s biosimilar of AbbVie’s $14B franchise drug

9 years ago

Knock it off: Biosimilars are not a 'knockoff' drug

9 years ago

Why we need to lower U.S. regulatory barriers around biosimilar approvals now

9 years ago

First page Previous page 339 340 341342343 Next page Last page